All In Biotech

Drug Trial Radar · NCT01766206

Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea

A Multicenter Post Marketing Surveillance Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ACWY Conjugate Vaccine(MenACWY-CRM) Administered According to the Prescribing Information to Healthy Subjects From 2 Months to 55 Years of Age in the Republic of South Korea.

Last checked: Nov 19, 2026Latest source record: Sep 21, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

3,948

Actual

Start

Mar 15, 2013

Primary completion

Jan 22, 2018

Study completion Jan 22, 2018

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jan 11, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 2 months, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A multicenter, single arm, post-marketing surveillance study. This study is a postlicensure requirement of the Korea Food and Drug Administration (KFDA) to provide continued safety evaluation of MenACWY in the Korean population from 2 months to 55 years of age, receiving MenACWY-CRM vaccination according to routine clinical practice and prescribing information.

Conditions

  • Meningococcal Disease

Interventions

  • MenACWY-CRM (Menveo)Biological

    One dose administered intramuscularly preferably into the anterolateral aspect of the thigh in infants or into the deltoid muscle in children, adolescents and adults.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects Reporting Any Local and Systemic Solicited Adverse Events (AEs)Time frame: From Day 1 of vaccination to Day 7 post vaccination
  2. Number of Subjects Reporting Any Unsolicited Adverse Events (AEs)Time frame: From Day 1 of vaccination to Day 7 post vaccination
  3. Number of Subjects Reporting Medically Attended AEs (MAAEs)Time frame: From Day 1 of vaccination to study termination (Day 29/early termination)
  4. Number of Subjects Reporting Serious AEs (SAEs)Time frame: From Day 1 of vaccination to study termination (Day 29/early termination)

Locations

54 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Ansan, South Korea

  • GSK Investigational Site

    Anyang, South Korea

  • GSK Investigational Site

    Bucheon-si, South Korea

  • GSK Investigational Site

    Busan, South Korea

  • GSK Investigational Site

    Changwon, South Korea

  • GSK Investigational Site

    Daegu, South Korea

  • GSK Investigational Site

    Daejeon, South Korea

  • GSK Investigational Site

    Daejeon, South Korea

  • GSK Investigational Site

    Donghae, South Korea

  • GSK Investigational Site

    Gimhae, South Korea

  • GSK Investigational Site

    Goyang-si, South Korea

  • GSK Investigational Site

    Goyang-si, Gyeonggi-do, South Korea

  • GSK Investigational Site

    Guro Gu, South Korea

  • GSK Investigational Site

    Gwangmyeong, South Korea

  • GSK Investigational Site

    Gwangmyeong, South Korea

  • GSK Investigational Site

    Gyeonggi-do, South Korea

  • GSK Investigational Site

    Gyeonggi-do, South Korea

  • GSK Investigational Site

    Gyeonggi-do, South Korea

  • GSK Investigational Site

    Gyeonggi-do, South Korea

  • GSK Investigational Site

    Incheon, South Korea

  • GSK Investigational Site

    Incheon, South Korea

  • GSK Investigational Site

    Incheon, South Korea

  • GSK Investigational Site

    Jeju City, South Korea

  • GSK Investigational Site

    Jeollanam Do, South Korea

  • GSK Investigational Site

    Kyeonggido, South Korea

  • GSK Investigational Site

    Pyeongtaek-si, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.